Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 7/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | QPCTL | Q9NXS2 | 3/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551525 | 1.00 | QPCT (0.44) | QPCTDYRK1ACLK4SYKLMNA | |
| SCHEMBL29550843 | 0.87 | MAPT (0.44) | QPCTDYRK1ACLK4SMN1; SMN2QPCTL | |
| SCHEMBL20522363 | 0.87 | MAPT (0.44) | QPCTDYRK1ACLK4SMN1; SMN2QPCTL | |
| SCHEMBL20522274 | 0.86 | SYK (0.49) | QPCTDYRK1ACLK4SYKLMNA | |
| SCHEMBL29551514 | 0.86 | SYK (0.49) | QPCTDYRK1ACLK4SYKLMNA | |
| SCHEMBL20522358 | 0.81 | QPCT (0.47) | QPCTDYRK1ACLK4 | |
| SCHEMBL29550383 | 0.81 | QPCT (0.47) | QPCTDYRK1ACLK4 | |
| SCHEMBL20522347 | 0.79 | KMT2A (0.48) | QPCTDYRK1ACLK4LMNASMN1; SMN2 | |
| SCHEMBL29550895 | 0.79 | KMT2A (0.48) | QPCTDYRK1ACLK4LMNASMN1; SMN2 | |
| SCHEMBL22712376 | 0.79 | QPCT (0.42) | QPCTDYRK1ACLK4LMNAQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110719910-B | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-07-21 | — | — | CN | claimed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | claimed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | claimed |
| EP-3601269-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2020-02-05 | — | — | EP | claimed |
| CN-110719910-A | Novel inhibitors | 前体生物药物股份公司 | 2020-01-21 | — | — | CN | claimed |
| WO-2018178384-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2018-10-04 | — | — | WO | claimed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110719910-B | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-3601269-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2020-02-05 | — | — | EP | disclosed |
| CN-110719910-A | Novel inhibitors | 前体生物药物股份公司 | 2020-01-21 | — | — | CN | disclosed |
| WO-2018178384-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | QPCT 6/4885DYRK1A 1140/4885CLK4 3637/4885 |
| US-20200377493-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | QPCT 3/4885DYRK1A 1606/4885CLK4 3420/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | QPCT 2/4885DYRK1A 1577/4885CLK4 3825/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | QPCT 2/4885DYRK1A 692/4885CLK4 2808/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | QPCT 3/4885DYRK1A 1632/4885CLK4 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.